Additionally, Doyle et al. (2011) reported a dose-dependent increase in proliferation in response to IGF1 in EAC cells and significantly higher serum IGF1 levels in EAC patients compared to those with Barrett's esophagus or controls [12]. Here, IGF1 is linked to esophageal adenocarcinoma.